The Russian pharmaceutical market continues to show strong positive growth. Its volume reached 2.9 trillion roubles by the end of 2025, an increase of 17%. At the same time, the market structure continues to shift towards generics and domestically produced drugs. These figures come from a study titled ‘Drivers of Pharma Market Growth’, prepared by the analytical agency DSM Group and the Ozon Pharmaceuticals Group. Experts believe that in 2026 the market will exceed 3 trillion roubles.
According to experts, market growth is driven primarily by generics and increasing market shares of domestic manufacturers. Prescription drugs already account for 72% of the market. In the long term, biotechnology will become a key driver. Analysts forecast that by 2030 the market will grow 1.6‑fold thanks to biosimilars, whose share will rise from 45% to 56%.
According to analysts’ forecasts, planned government program funding will remain at 2025 levels this year, with pharmacy sales again acting as a growth driver. The commercial segment will grow by 10–11%, mainly due to inflation. However, the study notes that the pharmacy segment is already seeing no growth in package volumes – this is due to reduced consumption of traditional drugs and a shift to larger pack sizes. This trend is even more pronounced in public procurement, especially for liquid dosage forms.
According to DSM Group data, Ozon Pharmaceuticals holds leading positions in key segments. The company is the largest player in the market in terms of drug sales in packages, and also leads in generic sales both in roubles and in packages. The Group ranks first among domestic manufacturers of unbranded generics in value terms.
In March, it was announced that Ozon Pharmaceuticals also topped the Forbes ranking of Russian pharmaceutical manufacturers for 2025. According to the publication, the company’s sales reached 63.6 billion roubles. It holds one of the largest drug portfolios – 556 marketing authorizations as of the end of last year.
